UBT251

Phase 3Small molecule

Novo Nordisk

UBT251 is one of 69 small molecule programs targeting Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Type 2 DiabetesNot yet recruiting

Diabetes Mellitus, Type 2Not yet recruiting

HepatitisPhase 2

Active, not recruiting

Type 2 DiabetesPhase 3

Not yet recruiting

Diabetes Mellitus, Type 2Phase 2

Not yet recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

UBT251

Novo Nordisk

Phase 3

1 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

Glargine

Eli Lilly

Preclinical

8 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Lovaza

AstraZeneca

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Overweight

NCT07395687

Q3 2027

Phase 2Recruiting

Hepatitis

NCT07145151

Q4 2027

Phase 3Not yet recruiting

Type 2 Diabetes

NCT07659574

Phase 2Not yet recruiting

Diabetes Mellitus, Type 2

NCT07668388

Q3 2030

Phase 2Recruiting

Phase II Clinical Study

NCT07134335

Clinical

Trials by Indication[1]

Hepatitis1 trial

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 2·NCT07145151·156 enrolled

Overweight1 trial

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT07395687·333 enrolled

Phase II Clinical Study1 trial

UBT251 Injection Phase II Clinical Study (CKD)

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 2·NCT07134335·180 enrolled

Diabetes Mellitus, Type 21 trial

Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT07668388·300 enrolled

Type 2 Diabetes1 trial

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

Not yet recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 3·NCT07659574·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for UBT251. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UBT251 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UBT251. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

UBT251

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q3 2030

Trials by Indication[1]

Hepatitis1 trial

Overweight1 trial

Phase II Clinical Study1 trial

Diabetes Mellitus, Type 21 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News